Aggressive anticancer treatment in the last 2 weeks of life

• Published in: ESMO open Vol. 9; no. 3; p. 102937
• Main Authors: Golob, N., Oblak, T., Čavka, L., Kušar, M., Šeruga, B.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2024
• Subjects: aggressive; anticancer treatment; end of life; specialist palliative care; systemic therapy; end of life; anticancer treatment; aggressive; systemic therapy; specialist palliative care
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2024.102937

There is a concern that terminally ill cancer patients may be aggressively treated due to the rapidly growing possibilities of anticancer treatment. The aim of this study was to evaluate the use of anticancer treatment at the end of life (EoL). This retrospective study included adult patients with advanced solid cancers who were treated at the Institute of Oncology Ljubljana and died of cancer between January 2015 and December 2019. A multiple logistic regression model was used to assess an association between the aggressiveness of anticancer treatment (i.e. systemic therapy, radiotherapy and surgery) in the last 2 weeks of life and year of death, age at death, sex, prognosis of cancer and enrolment into the specialist palliative care (SPC). We included 1736 patients in our analysis. Overall, 13.7% of patients were enrolled into the SPC and 14.4% received anticancer treatment in the last 2 weeks of life. The odds of receiving anticancer treatment significantly increased over time [odds ratio (OR) 1.15, 95% confidence interval (CI) 1.04-1.27]. There was an increased use of novel systemic therapy (e.g. small-molecule targeted therapy and immunotherapy) at the EoL. Older patients had significantly lower odds to receive anticancer treatment in the last 2 weeks of life as compared to younger patients (OR 0.96, 95% CI 0.95-0.98). As compared to patients receiving only a standard oncology care, those also enrolled into the SPC had significantly lower odds for anticancer treatment in the last 2 weeks of life (OR 0.22, 95% CI 0.12-0.43). Terminally ill cancer patients have increased odds for receiving anticancer treatment, especially novel systemic therapies, in the last 2 weeks of life. Younger patients and those not enrolled into the SPC are at particular risk for anticancer treatment at the EoL. •Terminally ill cancer patients may be aggressively treated due to the growing possibilities of anticancer treatment.•A probability of receiving anticancer treatment at the EoL increased over time.•There was an increased use of novel, very costly systemic therapies in the last 2 weeks of life.•Younger patients and those not enrolled into the SPC are at particular risk to receive anticancer treatment at the EoL.